Real-world effectiveness and safety of first-line pembrolizumab plus chemotherapy in patients aged ≥65 years with metastatic triple-negative breast cancer.
Year: 2026
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Aleksandra Konieczna, Malgorzata Meluch, Milos Holanek, Zuzana Bielčiková, Katarzyna Świderska, Malgorzata Pieniazek, Anika Pekala, Dana Dvorakova, Aneta Rozsypalova, Iveta Kolarova, Renata Soumarova, Bartosz Gasior, Magdalena Szymanik-Resko, Karolina Winsko-Szczęsnowicz, Malgorzata Podskarbi, Justyna Żubrowska, Joanna Kiszka, Lenka Rusinova, Zbigniew Nowecki, Miroslawa Puskulluoglu
Institutions: The Maria Sklodowska-Curie National Research Institute of Oncology, Masaryk University, Masaryk Memorial Cancer Institute, Pardubice Region, Charles University, Thomayer University Hospital, University Hospital Hradec Králové, University Hospital Kralovske Vinohrady, Štefan Kukura Hospital in Michalovce
Language: English
Subfield: Cancer Research
Domain: Life Sciences
Open Access status: closed
OpenAlex ID: W7162531660
Cites:
Cited by:
Related to: